Drug stewardship for RAS inhibitors and SGLT2 inhibitors in chronic kidney disease: stay on, restart
Nephrology Dialysis Transplantation · 2026
DOI: 10.1093/ndt/gfag008 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nephrology Dialysis Transplantation, 2026. Verfasst von Pim Bouwmans und 2 weiteren Autor:innen. Beteiligte Einrichtung: CARIM School for Cardiovascular Diseases, University of Maastricht, Maastricht, The Netherlands. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Renal Insufficiency, Chronic, Angiotensin Receptor Antagonists, Renin-Angiotensin System. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 96 Literaturangaben. Gefördert von: Swedish Research Council, Swedish Heart and Lung Foundation, Region Stockholm, ALF Medicine.
Abstract (Originalsprache)
Renin–angiotensin system inhibitors (RASis) and sodium–glucose co-transporter 2 inhibitors (SGLT2is) are the cornerstones of management for patients with chronic kidney disease (CKD). The use of these treatments is limited by frequent discontinuations, increasing the risk of death and compromising cardiovascular and renal health. This narrative review explores scenarios that lead to discontinuation: adverse effects (i.e. RASi-related acute kidney injury and hyperkalaemia), progression of CKD, acute illness, surgery and contrast administration. After AKI, we recommend restarting RASis and SGLT2is as soon as kidney function stabilises. For patients with mild-to-moderate hyperkalaemia on RASis, we advocate for thiazide-like diuretics and SGLT2is to avoid RASi discontinuation rather than routine dietary restrictions or potassium binders. We recommend against discontinuing RASis or SGLT2is when glomerular filtration rates decrease gradually. We review the evidence for sick-day rules and find it unconvincing. Withholding RASis before surgery has not been shown to reduce AKI. For low-risk procedures, the decision may be deferred to the anaesthetist. However, in settings where anaesthetists assess patients only shortly before surgery, or in high-risk cases, earlier multidisciplinary input is advised. We recommend stopping SGLT2is 2–3 days before elective procedures that involve fasting or anaesthesia. For the use of intra-arterial contrast, such as with coronary angiography, we do not recommend routinely withholding SGLT2is but we do suggest considering temporarily withholding RASis, especially in patients with advanced CKD or dehydration. We suggest promptly restarting RASis and SGLT2is after events; if both drugs have been withheld for more than a few days, and both are indicated, we suggest a staggered start. By reconciling, reviewing and thoughtfully prescribing medications, drug stewardship can maximize the time spent on these life-prolonging therapies, as long as this aligns with patients’ goals of care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CARIM School for Cardiovascular Diseases, University of Maastricht, Maastricht, The Netherlands.
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
- St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.
- Department of Health Research Methodology, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.
- Division of Nephrology, Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden.
ORCID-Profile: Pim Bouwmans, Catherine M Clase, Juan-Jesus Carrero
Förderung
- Swedish Research Council
- Swedish Heart and Lung Foundation
- Region Stockholm, ALF Medicine
Zitieren
APA
Bouwmans, P., Clase, C. M., & Carrero, J. J. (2026). Drug stewardship for RAS inhibitors and SGLT2 inhibitors in chronic kidney disease: stay on, restart. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag008
Vancouver
Bouwmans P, Clase CM, Carrero JJ. Drug stewardship for RAS inhibitors and SGLT2 inhibitors in chronic kidney disease: stay on, restart. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag008
BibTeX
@article{Bouwmans2026,
author = {Bouwmans, Pim and Clase, Catherine M and Carrero, Juan-Jesus},
title = {Drug stewardship for RAS inhibitors and SGLT2 inhibitors in chronic kidney disease: stay on, restart},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
doi = {10.1093/ndt/gfag008}
}
EUVIMED